Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
SRSF1
REST API REST API
Homo sapiens
SRSF1 is differentially expressed in 384 experiments: 162 organism parts: cerebellum, heart, ... (160 more);, 281 disease states: normal, cervical carcinoma, ... (279 more);, 104 cell types 477 cell lines 57 compound treatments and 92 other conditions.
Synonyms ASF, SFRS1, MGC5228, SF2, SRp30a, SF2p33
Orthologs Srsf1 (Mus musculus)   D4A9L2_RAT (Rattus norvegicus)   srsf1b (Danio rerio)   SRSF1_BOVIN (Bos taurus)   SRSF1 (Gallus gallus)   ENSCING00000000257 (Ciona intestinalis)   ENSCING00000007375 (Ciona intestinalis)   SF2 (Drosophila melanogaster)   srsf1 (Xenopus laevis)   SRSF1 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term RNA splicing, protein binding, nuclear speck, cytoplasm, nucleic acid binding, transcription from RNA polymerase II promoter, mRNA splice site selection, cardiac muscle contraction, nucleus, nucleotide binding, mRNA export from nucleus, nuclear mRNA splicing, via spliceosome, mRNA processing, nucleoplasm, RNA binding, in utero embryonic development, gene expression, RS domain binding, mRNA 3'-end processing, termination of RNA polymerase II transcription, nuclear mRNA 5'-splice site recognition, catalytic step 2 spliceosome
InterPro Term RRM_dom
UniProt Accession Q07955
Search EB-eye ENSG00000136450
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-15765, E-GEOD-6573, E-GEOD-1577, E-GEOD-3526, ... (37 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-4525, E-GEOD-19639, E-GEOD-18005, ... (41 experiments)

Factor Value U/D Experiments
SW480
4
E-MEXP-1014, E-GEOD-2509, E-MTAB-37, E-GEOD-18005
MCF-7
1
3
E-GEOD-20081, E-GEOD-5823, E-GEOD-19639, E-GEOD-3529
MCF-10A
2
E-TABM-420, E-GEOD-14990
MCF7
2
E-GEOD-5258, E-MTAB-37
MOLT4
2
E-MTAB-37, E-MTAB-62
T84
2
E-MTAB-37, E-GEOD-1474
471 more value(s).


Cell type

studied in E-GEOD-21668, E-GEOD-3920, E-MEXP-750, E-GEOD-20677, E-GEOD-2822, ... (51 experiments)

Factor Value U/D Experiments
embryonic stem cell
3
E-MEXP-930, E-GEOD-26672, E-GEOD-2248
721 B lymphoblast
2
2
E-AFMX-5, E-TABM-145
CD34+
2
E-AFMX-5, E-TABM-145
mononuclear
2
E-GEOD-26672, E-GEOD-13987
testis - germ cell
2
E-AFMX-5, E-TABM-145
mononuclear cell
1
E-GEOD-6053
98 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-2466, E-GEOD-1577, E-GEOD-12254, ... (80 experiments)

Factor Value U/D Experiments
chronic myelogenous leukemia
3
E-MTAB-37, E-GEOD-5550, E-MTAB-62
colon carcinoma
3
E-MTAB-62, E-MTAB-37, E-GEOD-3726
lung adenocarcinoma
3
E-MTAB-37, E-MEXP-231, E-MTAB-62
prostate carcinoma
1
3
E-MEXP-2034, E-MTAB-62, E-GEOD-96, E-MEXP-1327
lymphoma
2
E-MTAB-37, E-MTAB-62
uterine fibroid
2
E-GEOD-7307, E-MTAB-62
275 more value(s).


Compound treatment

studied in E-GEOD-5258, E-TABM-782, E-GEOD-5824, E-TABM-868, E-MEXP-1958, ... (35 experiments)

Factor Value U/D Experiments
none
5
8
E-TABM-782, E-GEOD-5824, E-MEXP-1601, E-GEOD-2803, E-MEXP-2345, ... (13 experiments)
ethanol
2
E-MEXP-2241, E-GEOD-3113
dimethyl sulfoxide
2
E-GEOD-6932, E-GEOD-5824
glutamine
2
E-MEXP-1335, E-MEXP-941
placebo
2
E-MEXP-1335, E-MEXP-1327
sapphyrin PCI-2055
1
E-GEOD-6400
51 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
DMSO
1
E-GEOD-19519
tunicamycin
1
E-GEOD-19519
thapsigargin
1
E-GEOD-19519


Biosource provider
studied in E-GEOD-20559

BioSourceProvider
studied in E-GEOD-19466, E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

cd1a
studied in E-GEOD-22601

cd34
studied in E-GEOD-22601

cd38
studied in E-GEOD-22601

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Chromosomal aberration
studied in E-TABM-125

Classifier
studied in E-GEOD-3493

Clinical history
studied in E-GEOD-22097, E-GEOD-19420, E-GEOD-19743, E-GEOD-7967, E-TABM-125, ... (9 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-TABM-176, E-GEOD-6710, E-GEOD-19348, ... (10 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-19743, E-GEOD-1614, E-GEOD-1638, E-GEOD-20033, E-GEOD-3140, ... (11 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-1323, E-GEOD-19743, E-GEOD-3325, E-GEOD-2509, E-TABM-147, ... (8 experiments)

double amplification
studied in E-GEOD-22601

Environmental stress
studied in E-GEOD-1643, E-GEOD-1518, E-GEOD-4086

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-16363

family id
studied in E-GEOD-19519

Family relationship
studied in E-MEXP-1425

Genetic modification
studied in E-GEOD-8023, E-GEOD-4025, E-MEXP-1482, E-GEOD-7578, E-GEOD-17385, ... (9 experiments)

Genotype
studied in E-TABM-763, E-MEXP-1437, E-GEOD-3494, E-GEOD-2466, E-GEOD-17476, ... (12 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-MEXP-2657, E-GEOD-20540, E-GEOD-22278, E-TABM-440, E-GEOD-837, ... (17 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-TABM-302, E-GEOD-21653, E-GEOD-20559, E-TABM-276, ... (7 experiments)

Individual
studied in E-TABM-325, E-MTAB-197, E-TABM-740, E-GEOD-2466, E-MEXP-2069, ... (39 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-2405, E-GEOD-12254, E-GEOD-9723, E-MEXP-561, ... (7 experiments)

Injury
studied in E-GEOD-19743

Irradiate
studied in E-GEOD-1977

Karyotype
studied in E-GEOD-7214

Ki67 ihc
studied in E-GEOD-21653

Labeling
studied in E-LGCL-5

Light
studied in E-GEOD-1725

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455, E-GEOD-9171

Media
studied in E-MEXP-765

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

Observation
studied in E-TABM-276

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-7540, E-GEOD-1801, E-GEOD-426, E-TABM-84

Organism status
studied in E-GEOD-19188

Original diagnosis
studied in E-GEOD-21521

P53 ihc
studied in E-GEOD-21653

Performer
studied in E-LGCL-5

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-7819, E-GEOD-19703, E-GEOD-1493, E-GEOD-22309, E-GEOD-1657, ... (8 experiments)

Population
studied in E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-21837, E-GEOD-1880, E-GEOD-19445, ... (7 experiments)

Replicate
studied in E-GEOD-18791, E-GEOD-10896

Rna integrity
studied in E-TABM-325

RNAi
studied in E-MEXP-2115, E-GEOD-1703, E-GEOD-12438, E-MEXP-1509, E-GEOD-1676, ... (9 experiments)

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-16797, E-GEOD-19743, E-MEXP-70, E-GEOD-17400

sbr grade
studied in E-GEOD-21653

Sex
studied in E-GEOD-2466, E-GEOD-7307

Stimulation
studied in E-GEOD-4883, E-GEOD-20114, E-GEOD-11886, E-GEOD-11428

stimulus
studied in E-GEOD-22103

Strain or line
studied in E-MEXP-1996, E-TABM-125

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

targeted_cell_type
studied in E-MEXP-70

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-GEOD-1926, E-TABM-276

tissue (organ)
studied in E-GEOD-22601

Transfection
studied in E-GEOD-14680

Translocation cyclin group
studied in E-GEOD-2912

Treatment
studied in E-GEOD-33562, E-GEOD-22152, E-GEOD-16837, E-MEXP-973, E-GEOD-19246, ... (8 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-4271, E-GEOD-4922, E-TABM-147

Vehicle
studied in E-GEOD-5258

Processing time: 0.347 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM